Description
Release form
Capsules.
Packaging
100 pcs
Indications
– osteolysis for metastases of malignant tumors in the bone and myeloma (multiple myeloma)
– hypercalcemia due to malignant tumors
– prevention of bone metastases in primary breast cancer.
Contraindications
– pregnancy
– lactation (breastfeeding)
– concomitant therapy with other
bisphosphonates – hypersensitivity to the drug and other bisphosphonates.
The drug Bonefos is not prescribed for children due to the lack of clinical experience with its use.
Caution should be exercised when using Bonefos in patients with impaired renal function.
Use during pregnancy and lactation
The drug is not recommended for use during pregnancy and lactation (breastfeeding) due to the lack of current data on the effect of Bonefos on reproductive function and fetal development.
Composition
1 caps. contains 500 mg disodium clodronate tetrahydrate, incl. disodium clodronate anhydrous 400 mg.
Dosage and administration of
An adequate amount of liquid should be taken during therapy with Bonefos.
In case of hypercalcemia due to malignant tumors, after normalizing the level of calcium in the blood serum, the drug is prescribed orally in a maintenance dose of 1.6 g / day.
For the treatment of hypercalcemia with the impossibility of iv administration, Bonefos is prescribed orally in high doses of 2.4-3.2 g / day, depending on the individual reaction of the patient, with a gradual transition to a maintenance dose of 1.6 g / day.
To prevent the development of bone metastases of primary breast cancer, the drug is prescribed orally at a dose of 1.6 g / day.
With osteolytic bone changes due to malignant neoplasms, without hypercalcemia, the dosage regimen is set individually. The recommended starting dose for oral administration is 1.6 g / day. If necessary, you can increase the dose. The maximum dose is 3.2 g / day.
Side effects of the digestive system: most often (up to 10%) – nausea, vomiting, diarrhea (most often manifested in mild form and occur when used in high doses), increased activity of hepatic transaminases (in rare cases – more than 2 times higher than the upper limit of the norm).
On the part of the water-electrolyte balance: asymptomatic hypocalcemia is possible rarely – hypocalcemia, accompanied by clinical manifestations.
From the endocrine system: an increase in the level of parathyroid hormone in the blood plasma is possible (usually in combination with a decrease in blood calcium level).
From the urinary system: there may be an increase in serum creatinine, proteinuria after rapid administration of the drug may develop acute renal failure.
Other: possible hypersensitivity reactions, changes in the concentration of alkaline phosphatase in serum (an increase in alkaline phosphatase is possible in patients with bone metastases), skin reactions in patients with bronchial asthma, with increased sensitivity to acetylsalicylic acid – respiratory failure, bronchospasm.
Drug Interaction
When Bonefos was co-administered with NSAIDs (most commonly with diclofenac), there were cases of renal dysfunction.
When Bonefos and estramustine phosphate are administered concurrently, the serum content of the latter decreases (up to 80%).
Clodronic acid forms, with divalent cations, insoluble complexes. Therefore, with the simultaneous use of Bonefos with food or drugs, containing divalent cations (including antacids, iron preparations), there is a significant decrease in the bioavailability of clodronic acid.
With the use of Bonefos with aminoglycosides, the risk of prolonged hypocalcemia is increased (use with caution).
Pharmaceutical Interaction
The compatibility of concentrate for the preparation of solution for injection with other drugs or solutions for injection has not been investigated. The drug should be diluted and administered only in accordance with the recommendations.
Storage conditions
Do not store above 25 ° C.
Shelf life
2 years.
Active ingredient
Clodron Chisloth
Terms and conditions
prescription
dosage form
capsules
Prescription
Prescription
For adults prescribed by a doctor
